An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone
NCT00774085 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 408
Last updated 2012-04-27
Summary
The purpose of this study is to assess treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
Conditions
Interventions
- OTHER
-
No intervention was given
Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
Sponsors & Collaborators
-
Janssen Cilag N.V./S.A.
lead INDUSTRY
Principal Investigators
-
Janssen-Cilag N.V./S.A., Belgium Clinical Trial · Janssen Cilag N.V./S.A.
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-11-30
- Primary Completion
- 2007-12-31
- Completion
- 2007-12-31
More Related Trials
-
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
NCT00253136 ·Status: COMPLETED ·Phase: PHASE3
-
A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia
NCT00236587 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
NCT00246194 ·Status: COMPLETED
-
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
NCT00216580 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
NCT00992407 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
NCT00132314 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 ·Status: COMPLETED ·Phase: PHASE4
-
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00539071 ·Status: COMPLETED ·Phase: PHASE4
-
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
NCT00261430 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
NCT00034775 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication
NCT00256997 ·Status: TERMINATED ·Phase: PHASE4
-
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
NCT00653406 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
NCT00495118 ·Status: COMPLETED ·Phase: PHASE3
-
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
NCT00158028 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
NCT00236353 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
NCT00044681 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
NCT00249132 ·Status: COMPLETED ·Phase: PHASE3
-
Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone
NCT00644852 ·Status: COMPLETED
-
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
NCT00246285 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00236457 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Major Depressive Disorder With Psychotic Features.
NCT00174590 ·Status: TERMINATED ·Phase: PHASE3
-
The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
NCT00034749 ·Status: COMPLETED ·Phase: PHASE3
-
Identification and Treatment of the Liability to Develop Schizophrenia
NCT00305474 ·Status: UNKNOWN ·Phase: PHASE4
-
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
NCT00378092 ·Status: COMPLETED ·Phase: PHASE4
-
Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
NCT01726335 ·Status: COMPLETED ·Phase: PHASE4